✦ LIBER ✦

Targeted treatment of prostate cancer

✍ Scribed by Xinning Wang; Lihong Yin; Pravin Rao; Robert Stein; Kelley M. Harsch; Zhenghong Lee; Warren D.W. Heston

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 142 KB
Volume: 102
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.21491

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer. More recently, preliminary trials have suggested that other targets could also be useful in the treatment of prostate cancer, and the proposed strategies for treatment have ranged from targeted toxins to immunotherapeutic agents. We provide an overview of some of these approaches, with an emphasis on those that employ prostate specific membrane antigen (PSMA) as a target. J. Cell. Biochem. 102: 571–579, 2007. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Targeting prostate cancer bone metastase

Targeting prostate cancer bone metastases

✍ Christopher Logothetis; Shi-Ming Tu; Nora Navone 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

Endocrine treatment in prostate cancer

✍ Louis J. Denis; Keith Griffiths 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 908 KB

Prostate cancer. Primary hormonal treatm

Prostate cancer. Primary hormonal treatment

✍ L Denis 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 920 KB

Interferon-β treatment of metastatic pro

Interferon-β treatment of metastatic prostate cancer

✍ M. A. Bulbul; R. P. Huben; G. P. Murphy 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

Combination treatment in M1 prostate can

Combination treatment in M1 prostate cancer

✍ P. Ferrari; G. Castagnetti; G. Ferrari; C. A. Pollastri; F. Tavoni; A. Dotti 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB

Localized prostate cancer. Relationship

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

✍ Thomas A. Stamey; Fuad S. Freiha; John E. McNeal; Elise A. Redwine; Alice S. Whi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

Background. Using the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute and American total mortality rates, the authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and then subtracted the incidence of